Telithromycin (BioDeep_00000009034)
Secondary id: BioDeep_00001871381
human metabolite blood metabolite Chemicals and Drugs
代谢物信息卡片
(3aR,4S,7R,9R,10R,11R,13R,15R,15aR)-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-{4-[4-(pyridin-3-yl)-1H-imidazol-1-yl]butyl}-tetradecahydro-1H-oxacyclotetradeca[4,3-d][1,3]oxazole-2,6,8,14-tetrone
化学式: C43H65N5O10 (811.473119)
中文名称: 泰利霉素
谱图信息:
最多检出来源 Homo sapiens(blood) 50%
分子结构信息
SMILES: CCC1OC(=O)C(C)C(=O)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)OC12C
InChI: InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33+,36-,37-,38-,40+,42-,43+/m1/s1
描述信息
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
Same as: D01078
同义名列表
7 个代谢物同义名
(3aR,4S,7R,9R,10R,11R,13R,15R,15aR)-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-{4-[4-(pyridin-3-yl)-1H-imidazol-1-yl]butyl}-tetradecahydro-1H-oxacyclotetradeca[4,3-d][1,3]oxazole-2,6,8,14-tetrone; Telithromycin; HMR-3647; RU-66647; HMR3647; RU66647; Ketek
数据库引用编号
13 个数据库交叉引用编号
- ChEBI: CHEBI:29688
- KEGG: C12009
- PubChem: 21881641
- PubChem: 70789201
- HMDB: HMDB0015111
- Metlin: METLIN43887
- Wikipedia: Telithromycin
- chemspider: 26329513
- CAS: 191114-48-4
- PMhub: MS000022771
- PubChem: 14168
- NIKKAJI: J982.785D
- RefMet: Telithromycin
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Robert Elsby, Victoria Hare, Hannah Neal, Samuel Outteridge, Catherine Pearson, Katie Plant, Rachel Upcott Gill, Philip Butler, Robert J Riley. Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1.
Drug metabolism and disposition: the biological fate of chemicals.
2019 01; 47(1):1-8. doi:
10.1124/dmd.118.083832. [PMID: 30348903] - Kohei Togami, Yoshiaki Hayashi, Sumio Chono, Kazuhiro Morimoto. Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin.
Biopharmaceutics & drug disposition.
2014 Sep; 35(6):321-9. doi:
10.1002/bdd.1900. [PMID: 24801141] - K Ikawa, E Kikuchi, J Kikuchi, M Nishimura, H Derendorf, N Morikawa. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.
Journal of clinical pharmacy and therapeutics.
2014 Aug; 39(4):411-7. doi:
10.1111/jcpt.12157. [PMID: 24661290] - K Togami, S Chono, K Morimoto. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells.
Die Pharmazie.
2012 May; 67(5):389-93. doi:
. [PMID: 22764569] - Ping Zhao, Manuela de L T Vieira, Joseph A Grillo, Pengfei Song, Ta-Chen Wu, Jenny H Zheng, Vikram Arya, Eva Gil Berglund, Arthur J Atkinson, Yuichi Sugiyama, K Sandy Pang, Kellie S Reynolds, Darrell R Abernethy, Lei Zhang, Lawrence J Lesko, Shiew-Mei Huang. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.
Journal of clinical pharmacology.
2012 Jan; 52(1 Suppl):91S-108S. doi:
10.1177/0091270011415528. [PMID: 22232759] - L H Javsicas, S Giguère, Ariel Y Womble. Disposition of oral telithromycin in foals and in vitro activity of the drug against macrolide-susceptible and macrolide-resistant Rhodococcus equi isolates.
Journal of veterinary pharmacology and therapeutics.
2010 Aug; 33(4):383-8. doi:
10.1111/j.1365-2885.2009.01151.x. [PMID: 20646201] - Kohei Togami, Sumio Chono, Toshinobu Seki, Kazuhiro Morimoto. Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections.
Drug development and industrial pharmacy.
2010 Jul; 36(7):861-6. doi:
10.3109/03639040903551319. [PMID: 20515406] - J H Lee, H E Kang, M G Lee. Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2010 Mar; 40(3):217-24. doi:
10.3109/00498250903470248. [PMID: 20039777] - Juha Grönlund, Teijo Saari, Nora Hagelberg, Ilkka K Martikainen, Pertti J Neuvonen, Klaus T Olkkola, Kari Laine. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
Journal of clinical pharmacology.
2010 Jan; 50(1):101-8. doi:
10.1177/0091270009336444. [PMID: 19755414] - Ayman M Noreddin, Walid F El-Khatib, Jason Aolie, Ahmed H Salem, George G Zhanel. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2009 Jul; 13(4):483-7. doi:
10.1016/j.ijid.2008.08.016. [PMID: 19046911] - Friederike Traunmüller, Manfred Fille, Christiane Thallinger, Christian Joukhadar. Multiple-dose pharmacokinetics of telithromycin in peripheral soft tissues.
International journal of antimicrobial agents.
2009 Jul; 34(1):72-5. doi:
10.1016/j.ijantimicag.2009.01.016. [PMID: 19380214] - Kohei Togami, Sumio Chono, Toshinobu Seki, Kazuhiro Morimoto. Distribution characteristics of telithromycin, a novel ketolide antimicrobial agent applied for treatment of respiratory infection, in lung epithelial lining fluid and alveolar macrophages.
Drug metabolism and pharmacokinetics.
2009; 24(5):411-7. doi:
10.2133/dmpk.24.411. [PMID: 19881252] - Joo H Lee, Yu K Cho, Young S Jung, Young C Kim, Myung G Lee. Effects of Escherichia coli lipopolysaccharide on telithromycin pharmacokinetics in rats: inhibition of metabolism via CYP3A.
Antimicrobial agents and chemotherapy.
2008 Mar; 52(3):1046-51. doi:
10.1128/aac.01210-07. [PMID: 18160519] - Scott Bolesta, Brian P Roslund. Elevated hepatic transaminases associated with telithromycin therapy: a case report and literature review.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2008 Jan; 65(1):37-41. doi:
10.2146/ajhp070164. [PMID: 18159037] - Joo H Lee, Myung G Lee. Effects of acute renal failure on the pharmacokinetics of telithromycin in rats: negligible effects of increase in CYP3A1 on the metabolism of telithromycin.
Biopharmaceutics & drug disposition.
2007 May; 28(4):157-66. doi:
10.1002/bdd.542. [PMID: 17377958] - Junko Kikuchi, Koichi Yamazaki, Eiki Kikuchi, Akitoshi Ishizaka, Masaharu Nishimura. Pharmacokinetics of telithromycin using bronchoscopic microsampling after single and multiple oral doses.
Pulmonary pharmacology & therapeutics.
2007; 20(5):549-55. doi:
10.1016/j.pupt.2006.05.006. [PMID: 17127087] - Sonja Eberl, Bertold Renner, Antje Neubert, Mareike Reisig, Iouri Bachmakov, Jörg König, Frank Dörje, Thomas E Mürdter, Andreas Ackermann, Harald Dormann, Karl G Gassmann, Eckhart G Hahn, Stefanie Zierhut, Kay Brune, Martin F Fromm. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.
Clinical pharmacokinetics.
2007; 46(12):1039-49. doi:
10.2165/00003088-200746120-00004. [PMID: 18027988] - Gary E Stein, Sharon Schooley, Kerin L Tyrrell, Diane M Citron, Ellie J C Goldstein. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens.
International journal of antimicrobial agents.
2007 Jan; 29(1):39-43. doi:
10.1016/j.ijantimicag.2006.08.041. [PMID: 17189093] - Joo Hyun Lee, Myung Gull Lee. Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
2007; 10(1):37-50. doi:
NULL. [PMID: 17498392] - Matthew T Burger, Christy Hiebert, Mehran Seid, Daniel T Chu, Lynn Barker, Mike Langhorne, Ribhi Shawar, Jolene Kidney, Manoj C Desai, Jacob J Plattner. Synthesis and antibacterial activity of novel C12 ethyl ketolides.
Bioorganic & medicinal chemistry.
2006 Aug; 14(16):5592-604. doi:
10.1016/j.bmc.2006.04.032. [PMID: 16697203] - Laura M Nenciu, Patrice Laberge, Daniel J G Thirion. Telithromycin-induced digoxin toxicity and electrocardiographic changes.
Pharmacotherapy.
2006 Jun; 26(6):872-6. doi:
10.1592/phco.26.6.872. [PMID: 16716140] - Michael J Rybak. Pharmacodynamics: relation to antimicrobial resistance.
The American journal of medicine.
2006 Jun; 119(6 Suppl 1):S37-44; discussion S62. doi:
10.1016/j.amjmed.2006.04.001. [PMID: 16735150] - Hiroyuki Nosaka, Masayuki Nadai, Miki Kato, Kazumasa Yasui, Hideo Yoshizumi, Mika Miyoshi, Ying Lan Zhao, Kenji Baba, Kenzo Takagi, Takaaki Hasegawa. Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats.
Life sciences.
2006 May; 79(1):50-6. doi:
10.1016/j.lfs.2005.12.022. [PMID: 16423372] - Lauri I Kajosaari, Mikko Niemi, Janne T Backman, Pertti J Neuvonen. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Clinical pharmacology and therapeutics.
2006 Mar; 79(3):231-42. doi:
10.1016/j.clpt.2005.11.002. [PMID: 16513447] - Shoji Yamaguchi, Ying Lan Zhao, Masayuki Nadai, Hideo Yoshizumi, Xiaobo Cen, Shoko Torita, Kenji Takagi, Kenzo Takagi, Takaaki Hasegawa. Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport.
Antimicrobial agents and chemotherapy.
2006 Jan; 50(1):80-7. doi:
10.1128/aac.50.1.80-87.2006. [PMID: 16377671] - C T Ong, P K Dandekar, C Sutherland, C H Nightingale, D P Nicolau. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae.
Chemotherapy.
2005 Oct; 51(6):339-46. doi:
10.1159/000088958. [PMID: 16224186] - Carman A Ciervo, Jun Shi. Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections.
Current medical research and opinion.
2005 Oct; 21(10):1641-50. doi:
10.1185/030079905x65466. [PMID: 16238904] - Christina Lippert, Seth Gbenado, Chunfu Qiu, Bruce Lavin, Steven J Kovacs. The bioequivalence of telithromycin administered orally as crushed tablets versus tablets swallowed whole.
Journal of clinical pharmacology.
2005 Sep; 45(9):1025-31. doi:
10.1177/0091270005279273. [PMID: 16100296] - Friederike Traunmüller, Rainer Gattringer, Markus A Zeitlinger, Wolfgang Graninger, Markus Müller, Christian Joukhadar. Determination of telithromycin in human plasma and microdialysates by high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2005 Aug; 822(1-2):133-6. doi:
10.1016/j.jchromb.2005.05.030. [PMID: 15990374] - Jean-Louis Démolis, Soraya Strabach, Françoise Vacheron, Christian Funck-Brentano. Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women.
British journal of clinical pharmacology.
2005 Aug; 60(2):120-7. doi:
10.1111/j.1365-2125.2005.02395.x. [PMID: 16042664] - Megan Nguyen, Eunice P Chung. Telithromycin: the first ketolide antimicrobial.
Clinical therapeutics.
2005 Aug; 27(8):1144-63. doi:
10.1016/j.clinthera.2005.08.009. [PMID: 16199242] - Tetsuro Muratani, Tetsuro Matsumoto, Susumu Arai. [In vitro antibacterial activities of telithromycin against clinical isolates of Neisseria gonorrhoeae].
The Japanese journal of antibiotics.
2005 Jun; 58(3):317-25. doi:
. [PMID: 16161757] - George G Zhanel, Christel Johanson, Nancy Laing, Tamiko Hisanaga, Aleksandra Wierzbowski, Daryl J Hoban. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
Antimicrobial agents and chemotherapy.
2005 May; 49(5):1943-8. doi:
10.1128/aac.49.5.1943-1948.2005. [PMID: 15855517] - T S Kuehnel, C Schurr, K Lotter, F Kees. Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis.
The Journal of antimicrobial chemotherapy.
2005 Apr; 55(4):591-4. doi:
10.1093/jac/dki034. [PMID: 15761076] - J Shi, S Chapel, G Montay, P Hardy, J S Barrett, D Sica, S K Swan, R Noveck, B Leroy, V O Bhargava. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment.
International journal of clinical pharmacology and therapeutics.
2005 Mar; 43(3):123-33. doi:
10.5414/cpp43123. [PMID: 15792396] - Jun Shi, Marc Pfister, Stephen G Jenkins, Sunny Chapel, Jeffrey S Barrett, Ruedi E Port, Dan Howard. Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.
Clinical pharmacokinetics.
2005; 44(3):317-29. doi:
10.2165/00003088-200544030-00007. [PMID: 15762772] - Jun Shi, Guy Montay, Vijay O Bhargava. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.
Clinical pharmacokinetics.
2005; 44(9):915-34. doi:
10.2165/00003088-200544090-00003. [PMID: 16122280] - Jun Shi, Guy Montay, Bruno Leroy, Vijay O Bhargava. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin.
Pharmacotherapy.
2005 Jan; 25(1):42-51. doi:
10.1592/phco.25.1.42.55621. [PMID: 15767219] - Rainer Gattringer, Eleonora Urbauer, Friederike Traunmüller, Markus Zeitlinger, Pejman Dehghanyar, Petra Zeleny, Wolfgang Graninger, Markus Müller, Christian Joukhadar. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers.
Antimicrobial agents and chemotherapy.
2004 Dec; 48(12):4650-3. doi:
10.1128/aac.48.12.4650-4653.2004. [PMID: 15561839] - George G Zhanel, Christel Johanson, Tamiko Hisanaga, Chris Mendoza, Nancy Laing, Ayman Noreddin, Aleksandra Wierzbowski, Daryl J Hoban. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
The Journal of antimicrobial chemotherapy.
2004 Dec; 54(6):1072-7. doi:
10.1093/jac/dkh475. [PMID: 15531596] - Liisa Törmäkangas, Hannu Alakärppä, Denise Bem David, Maija Leinonen, Pekka Saikku. Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.
Antimicrobial agents and chemotherapy.
2004 Oct; 48(10):3655-61. doi:
10.1128/aac.48.10.3655-3661.2004. [PMID: 15388416] - Michel Tintillier, Lotti Kirch, Carole Almpanis, Jean-Pierre Cosyns, Jean-Michel Pochet, Charles Cuvelier. Telithromycin-induced acute interstitial nephritis: a first case report.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2004 Aug; 44(2):e25-27. doi:
10.1053/j.ajkd.2004.04.045. [PMID: 15264209] - L Törmäkangas, E Saario, D Bem David, A Bryskier, M Leinonen, P Saikku. Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice.
The Journal of antimicrobial chemotherapy.
2004 Jun; 53(6):1101-4. doi:
10.1093/jac/dkh213. [PMID: 15117927] - S J Harnett, A P Fraise, J M Andrews, G Jevons, N P Brenwald, R Wise. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
The Journal of antimicrobial chemotherapy.
2004 May; 53(5):783-92. doi:
10.1093/jac/dkh180. [PMID: 15056651] - H Thadepalli, S K Chuah, A Vidad, S Gollapudi. Efficacy of telithromycin in the treatment of experimental Bacteroides fragilis intraabdominal abscess in the senescent mice.
Le infezioni in medicina.
2004 Mar; 12(1):44-50. doi:
. [PMID: 15329528] - Jun Shi, Guy Montay, Sunny Chapel, Pierre Hardy, Jeffrey S Barrett, Marshall Sack, Thomas Marbury, Suzanne K Swan, Ramon Vargas, Violette Leclerc, Bruno Leroy, Vijay O Bhargava. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment.
Journal of clinical pharmacology.
2004 Mar; 44(3):234-44. doi:
10.1177/0091270003262952. [PMID: 14973302] - David P Nicolau. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
2003 Dec; 9(4):292-6. doi:
10.1007/s10156-003-0279-x. [PMID: 14691648] - C Cantalloube, V Bhargava, E Sultan, F Vacheron, I Batista, G Montay. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment.
International journal of antimicrobial agents.
2003 Aug; 22(2):112-21. doi:
10.1016/s0924-8579(03)00128-6. [PMID: 12927950] - J Lorenz. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
International journal of clinical practice.
2003 Jul; 57(6):519-29. doi:
. [PMID: 12918892] - Anne-Claude Crémieux, Claudette Muller-Serieys, Xavière Panhard, Frédérique Delatour, Marina Tchimichkian, France Mentre, Antoine Andremont. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments.
Antimicrobial agents and chemotherapy.
2003 Jun; 47(6):2030-5. doi:
10.1128/aac.47.6.2030-2035.2003. [PMID: 12760893] - P Gehanno, E Sultan, V Passot, P Nabet, J Danon, P Romanet, P Attal. Telithromycin (HMR 3647) achieves high and sustained concentrations in tonsils of patients undergoing tonsillectomy.
International journal of antimicrobial agents.
2003 May; 21(5):441-5. doi:
10.1016/s0924-8579(03)00050-5. [PMID: 12727077] - José Mensa, Elisa García-Vázquez, Jordi Vila. [Macrolides, ketolides and streptogramins].
Enfermedades infecciosas y microbiologia clinica.
2003 Apr; 21(4):200-7; quiz 208, 219. doi:
NULL. [PMID: 12681133] - C Perret, B Lenfant, E Weinling, D H Wessels, H E Scholtz, G Montay, E Sultan. Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers.
Chemotherapy.
2002 Dec; 48(5):217-23. doi:
10.1159/000066766. [PMID: 12476037] - F Namour, E Sultan, M H Pascual, B Lenfant. Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration.
The Journal of antimicrobial chemotherapy.
2002 Jun; 49(6):1035-8. doi:
10.1093/jac/dkf062. [PMID: 12039900] - Katharina Semrad, Rachel Green. Osmolytes stimulate the reconstitution of functional 50S ribosomes from in vitro transcripts of Escherichia coli 23S rRNA.
RNA (New York, N.Y.).
2002 Apr; 8(4):401-11. doi:
10.1017/s1355838202029722. [PMID: 11991636] - Jun-Ichi Kadota, Yuji Ishimatsu, Tetsuji Iwashita, Yuichi Matsubara, Kazunori Tomono, Masao Tateno, Roza Ishihara, Claudette Muller-Serieys, Shigeru Kohno. Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.
Antimicrobial agents and chemotherapy.
2002 Mar; 46(3):917-21. doi:
10.1128/aac.46.3.917-921.2002. [PMID: 11850288] - D P Nicolau. Pharmacodynamic rationale for short-duration antibacterial therapy.
The Journal of infection.
2002 Feb; 44 Suppl A(?):17-23. doi:
NULL. [PMID: 12150491] - Vijay Bhargava, Bernard Lenfant, Catherine Perret, Marie-Helene Pascual, Eric Sultan, Guy Montay. Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin.
Scandinavian journal of infectious diseases.
2002; 34(11):823-6. doi:
10.1080/0036554021000026958. [PMID: 12578152] - D P Nicolau. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.
Infection.
2001 Dec; 29 Suppl 2(?):11-5. doi:
NULL. [PMID: 11785851] - C Muller-Serieys, P Soler, C Cantalloube, F Lemaitre, H P Gia, F Brunner, A Andremont. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
Antimicrobial agents and chemotherapy.
2001 Nov; 45(11):3104-8. doi:
10.1128/aac.45.11.3104-3108.2001. [PMID: 11600363] - O A Khair, J M Andrews, D Honeybourne, G Jevons, F Vacheron, R Wise. Lung concentrations of telithromycin after oral dosing.
The Journal of antimicrobial chemotherapy.
2001 Jun; 47(6):837-40. doi:
10.1093/jac/47.6.837. [PMID: 11389116] - A Bonnefoy, P Le Priol. Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics.
The Journal of antimicrobial chemotherapy.
2001 Apr; 47(4):471-3. doi:
10.1093/jac/47.4.471. [PMID: 11266424] - H M Yassin, L L Dever. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
Expert opinion on investigational drugs.
2001 Feb; 10(2):353-67. doi:
10.1517/13543784.10.2.353. [PMID: 11178347] - L Piroth, N Desbiolles, V Mateo-Ponce, L Martin, C Lequeu, P E Charles, H Portier, P Chavanet. HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy.
2001 Jan; 47(1):33-42. doi:
10.1093/jac/47.1.33. [PMID: 11152429] - F Namour, D H Wessels, M H Pascual, D Reynolds, E Sultan, B Lenfant. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses.
Antimicrobial agents and chemotherapy.
2001 Jan; 45(1):170-5. doi:
10.1128/aac.45.1.170-175.2001. [PMID: 11120961] - H Thadepalli, S K Chuah, S Qazi, F Thadepalli, S V Gollapudi. Bacteroides fragilis-induced intra-abdominal abscess in an experimental model treated with telithromycin (HMR 3647).
Chemotherapy.
2001 Jan; 47(1):43-9. doi:
10.1159/000048500. [PMID: 11125232] - G Drusano. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
2001; 7 Suppl 3(?):24-9. doi:
. [PMID: 11523559] - J A Balfour, D P Figgitt. Telithromycin.
Drugs.
2001; 61(6):815-29; discussion 830. doi:
10.2165/00003495-200161060-00016. [PMID: 11398913] - J M Andrews, T M Weller, J P Ashby, R M Walker, R Wise. The in vitro activity of ABT773, a new ketolide antimicrobial agent.
The Journal of antimicrobial chemotherapy.
2000 Dec; 46(6):1017-22. doi:
10.1093/jac/46.6.1017. [PMID: 11102425] - C Edlund, G Alván, L Barkholt, F Vacheron, C E Nord. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora.
The Journal of antimicrobial chemotherapy.
2000 Nov; 46(5):741-9. doi:
10.1093/jac/46.5.741. [PMID: 11062193] - R Fernández-Roblas, R Calvo, J Esteban, A Bryskier, F Soriano. The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against gram-positive bacilli and development of resistance.
The Journal of antimicrobial chemotherapy.
1999 Feb; 43(2):285-9. doi:
10.1093/jac/43.2.285. [PMID: 11252337] - P H Edelstein, M A Edelstein. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.
Antimicrobial agents and chemotherapy.
1999 Jan; 43(1):90-5. doi:
10.1128/aac.43.1.90. [PMID: 9869571] - F J Boswell, J M Andrews, J P Ashby, C Fogarty, N P Brenwald, R Wise. The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.
The Journal of antimicrobial chemotherapy.
1998 Dec; 42(6):703-9. doi:
10.1093/jac/42.6.703. [PMID: 10052892]